Global News

PPD earns award for innovation in training and development

Monday, May 20, 2013 08:00 AM

Pharmaceutical Product Development (PPD), a global CRO, has been named by Skillsoft as a winner of the 2013 Skillsoft Perspectives Innovation Award for Empowering Learning Cultures in the Enterprise.

More... »

Amgen, Novartis join Atlas Venture Fund IX as corporate strategic partners

Friday, May 17, 2013 12:25 PM

Atlas Venture, an early-stage venture capital firm that invests in technology and life sciences companies, has entered into Corporate Strategic Partnership (CSP) agreements with both Amgen, through its venture capital fund, Amgen Ventures, and Novartis. The CSP agreements are in conjunction with the closing of Atlas IX in which Amgen Ventures and Novartis are new limited partners. 

More... »

Soligenix initiates phase 1 study of SGX203 for pediatric Crohn's disease

Thursday, May 16, 2013 08:00 AM

Soligenix, a clinical stage biopharmaceutical company focused on inflammatory diseases and biodefense countermeasures, has initiated the first clinical study for development of SGX203 (oral beclomethasone 17, 21-dipropionate or oral BDP) for the treatment of pediatric Crohn's disease. The program has previously received Fast Track and Orphan Drug designations from the FDA for oral BDP as a treatment for pediatric Crohn's disease.

More... »

Vince & Associates Clinical Research acquired by the Altasciences Group

Wednesday, May 15, 2013 01:40 PM

The Altasciences Group of Quebec has acquired Vince & Associates Clinical Research.

More... »

Sorrento, Igdrasol acquire E.U. distribution rights to Cynviloq from Samyang

Wednesday, May 15, 2013 12:46 PM

Sorrento Therapeutics, a development-stage biopharmaceutical company, and Igdrasol, a developer of personalized paclitaxel, have acquired exclusive distribution rights from Samyang Biopharmaceuticals, a South Korean corporation, to Cynviloq (marketed as Genexol-PMR in South Korea) in the 27 countries of E.U.

More... »

Cobra Biologics, Vaccibody to manufacture DNA vaccine

Wednesday, May 15, 2013 12:21 PM

Cobra Biologics, an international clinical and commercial manufacturer of biologics and pharmaceuticals, and Vaccibody, a biotechnology company developing the next generation of vaccines against cancer and chronic infections, have signed an agreement to manufacture Vaccibody’s lead DNA vaccine candidate against HPV-induced malignancies, such as precancerous lesions found in cervical cancer.

More... »

Adaptive, BMS ink biomarker discovery collaboration agreement

Wednesday, May 15, 2013 11:57 AM

Adaptive Biotechnologies, a Seattle-based developer of next generation sequencing assays, has entered into a collaboration agreement with Bristol-Myers Squibb for the discovery of immunological biomarkers in oncology.

More... »

Astellas outlines plan to reshape its research framework, reallocate resources

Tuesday, May 14, 2013 02:44 PM

Tokyo-based Astellas Pharma has announced plans to reshape its research framework by introducing new initiatives to enhance the ability to generate innovative drugs.

More... »

Certara, Veristat partner for combined service offerings

Tuesday, May 14, 2013 01:37 PM

Certara, a provider of software and scientific consulting services from drug discovery through clinical development, and Veristat, a full-service CRO, have formed an alliance to offer combined services to their clients.

More... »

BIO, ViS Research Institute target pediatric trials

Tuesday, May 14, 2013 01:27 PM

The Biotechnology Industry Organization and the ViS Research Institute have launched an initiative aimed at improving the efficiency of clinical development for pediatric therapeutics. BIO and its member companies will work with ViS to use its online analytics platform to evaluate global pediatric clinical research infrastructure, identify pediatric patient populations and empower clinical research collaboration.

More... »